Fast-growing cancer could be slowed by common blood pressure drug, research shows

Researchers at the University of Pennsylvania found that the long‑standing blood‑pressure drug hydralazine directly binds and inhibits the oxygen‑sensing enzyme 2‑aminoethanethiol dioxygenase (ADO), shutting down a hypoxia survival pathway that tumors exploit; structural work (including X‑ray crystallography) shows how hydralazine silences ADO. In cell‑culture experiments with human glioblastoma, hydralazine stopped proliferation and induced senescence within three days without killing cells, indicating a potential route to control aggressive, relapse‑prone tumors; because hydralazine is already FDA‑approved it could be repurposed more quickly, but the results are preliminary and limited to lab studies pending animal and human safety/efficacy testing.

Analysis

Researchers at the University of Pennsylvania identified that the established antihypertensive hydralazine directly binds and inhibits the enzyme 2-aminoethanethiol dioxygenase (ADO), an intracellular oxygen sensor; structural work including X-ray crystallography defined how hydralazine silences ADO. Hydralazine has been used clinically since the 1950s, which the team highlights as a potential advantage for repurposing timelines if the mechanism translates beyond cells. In cell-culture experiments with human glioblastoma, three-day treatment with hydralazine halted proliferation and induced senescence—cells became larger and flatter and lost the ability to divide—rather than causing outright cell death, a phenotype that could limit tumor regrowth. The authors and press release stress that these findings are preliminary: experiments are limited to in vitro models and the next steps are animal and human testing to assess safety and efficacy; sentiment around the discovery is mildly positive with low near-term market impact (market_impact_score 0.18), reflecting early-stage promise but substantial translational risk.

Key Decisions for Investors

• Monitor announcements of animal studies and any clinical trial initiations testing hydralazine or ADO inhibitors, as in vivo efficacy/safety will be the primary catalyst
• Avoid reallocating significant capital based solely on these cell-culture results; treat commercial prospects as speculative until positive animal or human data are reported
• Watch for licensing, partnership, or trial-asset transactions involving hydralazine repurposing or ADO-targeted programs as potential near-term value catalysts
• If pursuing exposure, limit positions to small, tactical allocations to companies with demonstrated translational/clinical execution and use hedges given the high probability of preclinical-to-clinic attrition